摘要
目的:探讨二甲双胍对2型糖尿病合并动脉粥样硬化患者基质金属蛋白酶2(Matrix metalloproteinase-2,MMP-2)及IL-6、8的影响。方法:51例2型糖尿病患者根据颈动脉内中膜厚度(IMT)及斑块分为动脉粥样硬化组(35例)和无动脉粥样硬化组(16例)。动脉粥样硬化组中又分为治疗组(20例,二甲双胍治疗24周)和未治疗组(15例)。随访24周,治疗前、后均检测生化及MMP-2、IL-6、8等指标。结果:(1)Spearman相关分析显示体重指数(BMI)和MMP-2和IL-6、8显著正相关(P<0.01)。(2)治疗前动脉粥样硬化组MMP-2和IL-6、8与无动脉粥样硬化组比较,显著升高(P<0.01),与无动脉粥样硬化组比较,TG显著高,而HDL-C显著降低(P<0.05)。(3)与治疗前比较,治疗组治疗24周后MMP-2和IL-6、8明显下降(P<0.01),TC、TG和低密度脂蛋白胆固醇(LDL-C)显著下降(P<0.01),HDL-C上升(P<0.01)。结论:2型糖尿病合并动脉粥样硬化患者MMP-2和IL-6、8明显升高。二甲双胍降低血糖、体重外,可以通过减低MMP-2和IL-6、8水平来发挥其抗动脉粥样硬化作用。
Objective:To investigate the effect of metformin on the MMP-2 and IL-6, 8 in patients with type 2 diabetes. Methods.. To recruit 51 T2DM patients with atherosclerosis. The patients were treated with metformin for 24 weeks without a change in previous medications. Levels of plasma lipids and MMP-2 and IL-6, 8 were measured. To compare the treatment effects between three groups after 24 weeks treatment. Results: After metformin for 24 weeks, MMP-2 and II.-6, 8, TC and TG were lower than before, HDL-C were increased. Conclusion.. Beneficial effects of metformin may be due to non-lipid actions, metformin can exert anti-atherosclerotic effect by reducing the expression of MMP-2 and IL-6,8.
出处
《医学理论与实践》
2013年第21期2806-2808,共3页
The Journal of Medical Theory and Practice